Current pharmacological treatments, including sodium–glucose cotransporter-2(SGLT2) inhibitors, renin–angiotensin system inhibitors, glucagon-like peptide-1 (GLP-1) agonists, nonsteroidal mineralocorticoid receptor antagonists, and combination therapies have demonstrated potential in slowing CKD progression and improving cardiovascular outcomes, but their effectiveness varies among individual patients [23]. This evidence concerns the gene SLC5A2 and chronic kidney disease.